[UPDATED ISRAELI GUIDELINES FOR THE TREATMENT OF DYSLIPIDEMIA 2020].

Area of Science:

• Cardiology
• Atherosclerosis Research
• Lipid Metabolism

Background:

• Atherosclerotic cardiovascular diseases (ASCVD) remain a major global health concern despite declining mortality rates.
• Low-density lipoprotein (LDL) cholesterol is a key factor in atherosclerosis development.
• Previous guidelines focused on statins for dyslipidemia, but newer therapies offer additional benefits.

Purpose of the Study:

• To update guidelines for ASCVD prevention and treatment based on recent evidence.
• To provide recommendations for risk stratification, target LDL cholesterol goals, and treatment strategies.
• To incorporate newer LDL-lowering therapies into clinical practice.

Main Methods:

• Formulation of updated guidelines by a multidisciplinary committee of Israeli medical societies.
• Review of recent studies on LDL cholesterol-lowering drugs (statins, ezetimibe, PCSK9 inhibitors).
• Analysis of evidence supporting lower LDL cholesterol targets and combination therapies.

Main Results:

• Lower LDL cholesterol targets provide additional ASCVD risk reduction without a discernible safety threshold.
• Combination therapies, including ezetimibe and PCSK9 inhibitors with statins, offer incremental benefits.
• Evidence supports the use of these newer agents in specific patient subgroups.

Conclusions:

• Updated guidelines emphasize more aggressive LDL cholesterol lowering for ASCVD prevention.
• Novel treatment strategies involving combination therapy are recommended.
• Revised risk stratification and target goals aim to improve patient outcomes in ASCVD.